clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Discitis D015299 2 associated lipids
Iris Diseases D007499 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Fractures, Open D005597 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Cysts D003560 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Foot Diseases D005534 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Prurigo D011536 4 associated lipids
Confusion D003221 4 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Duodenitis D004382 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kamberoglou D et al. Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. 2001 Aliment. Pharmacol. Ther. pmid:11552924
Neri M et al. Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:7986974
Zullo A et al. High eradication rates of Helicobacter pylori with a new sequential treatment. 2003 Aliment. Pharmacol. Ther. pmid:12641522
Lane JA et al. Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. 2011 Aliment. Pharmacol. Ther. pmid:21366634
Bazzoli F et al. Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. 2002 Aliment. Pharmacol. Ther. pmid:11856090
Grimley CE et al. Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. 1999 Aliment. Pharmacol. Ther. pmid:10383520
Houben MH et al. Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. 1999 Aliment. Pharmacol. Ther. pmid:10383522
Bortolotti M et al. Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. 1998 Aliment. Pharmacol. Ther. pmid:9798808
John Albert M et al. High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. 2006 Aliment. Pharmacol. Ther. pmid:17059517
Furuta T et al. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. 2007 Aliment. Pharmacol. Ther. pmid:17697203
Veldhuyzen Van Zanten S et al. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. 2000 Aliment. Pharmacol. Ther. pmid:11121908
Kim YS et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. 2011 Aliment. Pharmacol. Ther. pmid:21923713
Gisbert JP et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. 2000 Aliment. Pharmacol. Ther. pmid:11012477
Graham DY et al. Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10102946
Zanten SJ et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. 1999 Aliment. Pharmacol. Ther. pmid:10102960
Tankovic J et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. 2001 Aliment. Pharmacol. Ther. pmid:11328266
Feydt-Schmidt A et al. Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. 2002 Aliment. Pharmacol. Ther. pmid:12452940
Nista EC et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. 2004 Aliment. Pharmacol. Ther. pmid:15569121
Drouet M et al. [Unusual clinical form of amoxicillin allergy]. 1996 Allerg Immunol (Paris) pmid:9011169
Can C et al. Symmetrical drug-related intertriginous and flexural exanthema induced by two different antibiotics. Allergol Immunopathol (Madr) pmid:23253684
Gangemi S et al. Immediate reaction to clarithromycin. 2001 Jan-Feb Allergol Immunopathol (Madr) pmid:11449533
Gaig P et al. Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. 2002 Sep-Oct Allergol Immunopathol (Madr) pmid:12396958
Karakaya G et al. Determining safe antibiotics for drug hypersensitive patients with the alternative method of double-triple test. Allergol Immunopathol (Madr) pmid:19080798
Malheiro D et al. Nimesulide-induced fixed drug eruption. 2005 Sep-Oct Allergol Immunopathol (Madr) pmid:16287549
Seitz CS et al. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. Allergol Immunopathol (Madr) pmid:21269750
Moreira A et al. Is Helicobacter pylori infection associated with chronic idiopathic urticaria? Allergol Immunopathol (Madr) pmid:12890412
Brož P et al. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. 2012 Allergy pmid:22435670
Igea JM and Lázaro M Hypersensitivity reaction to clarithromycin. 1998 Allergy pmid:9491242
Ben-Shoshan M et al. Anaphylactic reaction to clarithromycin in a child. 2009 Allergy pmid:19222423
Siddiqui S and Brightling CE Airways disease: phenotyping heterogeneity using measures of airway inflammation. 2007 Allergy Asthma Clin Immunol pmid:20525145
Xepapadaki P et al. Atypical bacteria and macrolides in asthma. 2008 Allergy Asthma Clin Immunol pmid:20525132
Desrosiers M et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. 2011 Allergy Asthma Clin Immunol pmid:21310056
Wedi B et al. Urticaria and infections. 2009 Allergy Asthma Clin Immunol pmid:20066173
Thong BY Update on the management of antibiotic allergy. 2010 Allergy Asthma Immunol Res pmid:20358021
Park SJ et al. Fulminant and Fatal Multiple Organ Failure in a 12-Year-Old Boy With Mycoplasma pneumoniae Infection. 2012 Allergy Asthma Immunol Res pmid:22211173
Kim MH et al. A case of chlorpheniramine maleate-induced hypersensitivity with aspirin intolerance. 2011 Allergy Asthma Immunol Res pmid:21217928
Hong SJ The Role of Mycoplasma pneumoniae Infection in Asthma. 2012 Allergy Asthma Immunol Res pmid:22379599
Kariyawasam HH and Scadding GK Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches. 2011 Allergy Asthma Immunol Res pmid:21966602
Damianos AJ and McGarrity TJ Treatment strategies for Helicobacter pylori infection. 1997 Am Fam Physician pmid:9191460
Karlstadt RG and Walker K Update on prescribing information for pantoprazole. 2003 Am Fam Physician pmid:12674447
Gregory DS Pertussis: a disease affecting all ages. 2006 Am Fam Physician pmid:16913160
Chaisson R Clarithromycin is effective against M. avium complex in AIDS. 1992 Am Fam Physician pmid:1456199
Elston D Nontuberculous mycobacterial skin infections: recognition and management. 2009 Am J Clin Dermatol pmid:19658440
Rebora A The management of rosacea. 2002 Am J Clin Dermatol pmid:12180896
Scheinfeld N Confluent and reticulated papillomatosis : a review of the literature. 2006 Am J Clin Dermatol pmid:17007541
Zeegelaar JE and Faber WR Imported tropical infectious ulcers in travelers. 2008 Am J Clin Dermatol pmid:18572973
Chang SL et al. Bilateral sporotrichoid lymphocutaneous dermatosis in a drug abuser: case report and review of the literature. 2008 Am J Clin Dermatol pmid:18973406
Wedi B and Kapp A Helicobacter pylori infection in skin diseases: a critical appraisal. 2002 Am J Clin Dermatol pmid:12010072
Curth HM et al. Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study. 2015 Am J Clin Dermatol pmid:26334425
Parsad D et al. A guide to selection and appropriate use of macrolides in skin infections. 2003 Am J Clin Dermatol pmid:12762831
Yeh I et al. Cutaneous mycobacterial spindle cell pseudotumor: a potential mimic of soft tissue neoplasms. 2011 Am J Dermatopathol pmid:21712686
Song H et al. Cutaneous nontuberculous mycobacterial infection: a clinicopathological study of 7 cases. 2009 Am J Dermatopathol pmid:19384062
Lai J et al. Epithelioid histiocytic infiltrate caused by Mycobacterium scrofulaceum infection: a potential mimic of various neoplastic entities. 2013 Am J Dermatopathol pmid:22935892
Sketris IS et al. Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies. 2004 Am J Geriatr Pharmacother pmid:15555476
Hsu O et al. Decreased plasma efavirenz concentrations in a patient receiving rifabutin. 2010 Am J Health Syst Pharm pmid:20852162
Johnson TJ and Hedge DD Esomeprazole: a clinical review. 2002 Am J Health Syst Pharm pmid:12132559
Halpern MT et al. Cost-effectiveness of gemifloxacin: results from the GLOBE study. 2002 Am J Health Syst Pharm pmid:12132563
Chahine C et al. Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori. 2001 Am J Health Syst Pharm pmid:11596697
Henneman A and Thornby KA Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics. 2012 Am J Health Syst Pharm pmid:22644980
Kaeser YA et al. Severe hypotension and bradycardia associated with verapamil and clarithromycin. 1998 Am J Health Syst Pharm pmid:9825040
Three new studies expand understanding of MAC therapy. 1996 Am J Health Syst Pharm pmid:8899122
Peloquin CA and Berning SE Advice on treatment of Mycobacterium avium complex infection. 1997 Am J Health Syst Pharm pmid:9161632
H. pylori treatment recognized by FDA. 1996 Am J Health Syst Pharm pmid:8725200
Sonnenberg A et al. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. 1999 Am J Manag Care pmid:10345967
Lilley LL and Guanci R A dangerous combination. 1998 Am J Nurs pmid:9612423
Antibiotic gets FDA nod for MAC treatment. 1994 Am J Nurs pmid:8304386
Evans AK and Cunningham MJ Atypical mycobacterial cervicofacial lymphadenitis in children: a disease as old as mankind, yet a persistent challenge. 2005 Sep-Oct Am J Otolaryngol pmid:16137534
Hashisaki GT Update on macrolide antibiotics. 1995 May-Jun Am J Otolaryngol pmid:7661309
Einarson A et al. A prospective controlled multicentre study of clarithromycin in pregnancy. 1998 Am J Perinatol pmid:9890248
Jacoby EB and Porter KB Helicobacter pylori infection and persistent hyperemesis gravidarum. 1999 Am J Perinatol pmid:10355915
Abouesh A and Hobbs WR Clarithromycin-induced mania. 1998 Am J Psychiatry pmid:9812131
Brooks JO and Hoblyn JC Secondary mania in older adults. 2005 Am J Psychiatry pmid:16263839
Keicho N and Kudoh S Diffuse panbronchiolitis: role of macrolides in therapy. 2002 Am J Respir Med pmid:14720066
Darkes MJ and Perry CM Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. 2003 Am J Respir Med pmid:14720016
Tohnai A et al. Clarithromycin suppresses proliferation of rat nasal epithelium exposed to endotoxin. 1998 Nov-Dec Am J Rhinol pmid:9883303
Zeng M et al. Comparison of efficacy of mometasone furoate versus clarithromycin in the treatment of chronic rhinosinusitis without nasal polyps in Chinese adults. 2011 Nov-Dec Am J Rhinol Allergy pmid:22185725
Gupta AK and Moorman CT Nocardia nova infection after primary anterior cruciate ligament reconstruction with tibialis anterior allograft. 2010 Am J Sports Med pmid:20375367
Yang X et al. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients. Am J Ther pmid:25923229
Feng L et al. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther pmid:25569598
McCarthy DM et al. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. 2003 Sep-Oct Am J Ther pmid:12975717
Chang NL et al. Clarithromycin-Induced Torsades de Pointes. Am J Ther pmid:25057773
Kurowski K et al. Clarithromycin-induced alterations in vaginal flora. 2000 Am J Ther pmid:11317173
Alkim H et al. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther pmid:26808355
Jacobson TA Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. 2004 Am. J. Cardiol. pmid:15518608
Hsu CH et al. The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients. 2006 Am. J. Chin. Med. pmid:17163582
Wang YC et al. In vitro activity of Impatiens balsamina L. against multiple antibiotic-resistant Helicobacter pylori. 2009 Am. J. Chin. Med. pmid:19655409
Sauter C and Blum S Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease. 2003 Am. J. Clin. Oncol. pmid:12576932
Kapadia M et al. Invasive Streptomyces infections: six cases and literature review. 2007 Am. J. Clin. Pathol. pmid:17369139
Buchanan Keller K and Lemberg L Torsade. 2008 Am. J. Crit. Care pmid:18158394
Jaup BH and Norrby A Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7771426
de Bortoli N et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. 2007 Am. J. Gastroenterol. pmid:17313499
Sullivan B et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. 2002 Am. J. Gastroenterol. pmid:12385435
Ozmen MM and Johnson CD Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? 1995 Am. J. Gastroenterol. pmid:7661197
Savarino V et al. New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. 1995 Am. J. Gastroenterol. pmid:7717343
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Sirimontaporn N et al. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. 2010 Am. J. Gastroenterol. pmid:20010919
Basu PP et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. 2011 Am. J. Gastroenterol. pmid:21989146
Jarbol DE et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. 2006 Am. J. Gastroenterol. pmid:16771937
Nakao K et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. 1997 Am. J. Gastroenterol. pmid:9177520
Maconi G et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? 2001 Am. J. Gastroenterol. pmid:11232676